About the company

C

iana Therapeutics is a clinical development-stage company led by an experienced team developing new therapies within ophthalmology and with an initial focus on Diabetic Retinopa­thy.

Diabetic Retinopathy is a serious condition that afflicts 30% of patients with diabetes and leads to vision loss and blindness. Ciana is a spin-out from a pharmaceutical company that originally developed their lead drug therapy, Danegaptide. Danegaptide has a proven safety profile in humans, strong efficacy in pre-clinical therapeutic models and can uniquely address the need for more effective and earlier treatments in Diabetic Retinopathy.

Experienced Team with Valuable Expertise

Key personnel, advisors and directors already identified

Ulrik Mouritzen, MD
Ulrik Mouritzen, MDFounder & CEO
Drug developer with 20 years of experience in early and late clinical development phases VP, Head of Clinical at Zealand for 6 years and lead on Danegaptide.
Med. Dir. for 11 years including US expatriation to Princeton, NJ.
Brad Young, PhD, MBA
Brad Young, PhD, MBACo-Founder & CBO
Biotech executive, investor and consultant with 20 years of clinical science and business experience.
Successful track record of developing and commercializing innovative targeted medicine products and technologies.

Directors

Bernard E. Lyons, PhD.
Former CEO of three medical device companies

Harold Van Wart, PhD.
Former CEO of two therapeutics companies

Scientific Advisors

Prof. Michael Larsen, MD, DMSc (RH)
Prof. Sayon Roy, PhD, FARVO (BMC)

Additional Team

Senior CMC advisors contracted
Toxicology consultant contracted
Regulatory advisor
VP / Director Finance, part time
Director R&D
Leading CDMO vendors

Work with us

Developing a front-line treatment to combat vision loss and blindness in diabetes

CONTACT US